Coreline Soft, a medical image software developer, said Wednesday that it would supply its solutions to Chinese and Taiwanese hospitals, following its recent participation in the largest lung cancer diagnosis project in Europe.

Coreline Soft has recently advanced to the Chinese and Taiwanese markets.
Coreline Soft has recently advanced to the Chinese and Taiwanese markets.

Coreline Soft will provide its AVIEW COPD solution to the People’s Hospital of Ningxia, one of the largest hospitals in China, and the National Taiwan University Hospital (NTUH). AVIEW COPD solution can make an auto analysis on lungs disease using artificial intelligence techniques.

AVIEW COPD is a solution that makes an automated quantitative diagnosis of chronic obstructive pulmonary disease (COPD) with AI. It can diagnose all four analysis criteria -- pulmonary emphysema, bronchus, air trapping, and blood vessels. It uses deep learning and applies a fully automated processing algorithm to provide the latest quantitative analysis and achieve zero waiting hours.

Coreline specializes in diagnosing pulmonary disease. It has provided the national lung cancer screening solution for five consecutive years. The company also has recently become the solution provider for EU-funded “4 In The Lung Run (4ITLR),” one of Europe’s largest lung cancer screening projects, and Germany’s national lung cancer diagnosis program.

Coreline has lately been focusing on the Chinese and Taiwanese markets. This is because the number of lung cancer patients in China has also shown a consistent increase. According to Global Data, a statistical analysis company in the pharmaceutical market, 46 percent of the world’s lung cancer patients were Chinese in 2015. The share was estimated to rise to 62 percent in 2020.

Coreline Soft also became the first company to win Taiwan’s certificate in the overseas AI sector in April, with AVIEW. In addition, many of Coreline Soft’s AI solutions on lungs disease have been introduced to major hospitals in China.

As the detailed study on the lungs of patients in China and Taiwan expands, Coreline plans to speed up its advancement in the Chinese market.

Copyright © KBR Unauthorized reproduction, redistribution prohibited